Press contact : Shelley Epstein, EVP, Corporate & Public Affairs

Imagia Cybernetics & Canexia Health Merge to Supercharge
Precision Oncology Accessibility

Merger includes C$20 million investment to accelerate access to genomics-based testing for cancer treatment by combining Canexia Health’s advanced molecular cancer solutions with Imagia Cybernetics’ healthcare and AI expertise

Combined, Imagia and Canexia will increase access to precision oncology at the community level

In addition to working with four leading pharmaceutical companies, Imagia and Canexia are integrated with 20 hospital systems and reference labs around the world. Their expertise in genomics, oncology, artificial intelligence, and informatics will enable health systems to bring testing in-house, delivering precision oncology to patients no matter where they live.

Quick look

  • Merger of Imagia Cybernetics, an AI-healthcare company that accelerates oncology solutions generated from real world data, with Canexia Health, an oncology innovator that streamlines complex cancer genomic information which allows oncologists to identify optimal treatment selection and patient monitoring.
  • Combining expertise in genomics, oncology, artificial intelligence, and informatics to enable health systems to bring testing in-house, delivering precision oncology to patients no matter where they live.
  • The new company, Imagia Canexia Health, improves accessibility through cost-effective local testing, thereby reducing expenses and generating faster results.

FREQUENTLY ASKED QUESTIONS

Why are Imagia and Canexia Health merging?

The merger of Imagia Cybernetics and Canexia Health combines expertise in genomics, oncology, artificial intelligence, and informatics to enable health systems to bring testing in-house, delivering precision oncology to patients no matter where they live. Imagia is an AI-healthcare company that accelerates oncology solutions generated from real world data, and Canexia Health is an oncology innovator that streamlines complex cancer genomic information which allows oncologists to identify optimal treatment selection and patient monitoring.

The new company, Imagia Canexia Health, improves accessibility through cost-effective local testing, thereby reducing expenses and generating faster results.

Who participated in the funding?

The merger includes C$20 million in funding with participation from: BDC Capital’s Women in Technology Venture Fund, Desjardins Capital, and PacBridge Capital.

What is the new company name?

At the time of announcing the merger, Imagia and Canexia Health will retain their respective names until brand integration is completed. This process may take up to 6-8 months. We do expect the company to operate under a new name and details will be forthcoming.

About Imagia

Imagia, an artificial intelligence and healthcare company, develops digital medical innovations that aim to improve the health of cancer patients and those with other heavy-burden diseases. Through its collaborative ecosystem, Imagia EVIDENS™ enables hospitals, medical device manufacturers, pharmaceutical companies, and diagnostic companies around the world to access and utilize healthcare data while preserving data privacy. Headquartered in Montréal, Imagia’s mission is to unlock the potential of data across all organizations to achieve collaborative, medical breakthroughs. www.imagia.com

About Canexia Health

Canexia Health makes high-quality cancer genomic information accessible and affordable with our clinically-validated assays, informatics, and support. Our suite of genomics-based cancer tests is clinically actionable and cost-effective, designed to improve cancer treatment and monitoring. With our extensive scientific experience, specialized genomics-based tests, and support from pharmaceutical and diagnostic partners, we are leading the shift towards precision oncology. www.canexiahealth.com

Copyright 2022 © Imagia Cybernetics Inc. All rights reserved. Prescribing AI. Improving Lives Web design by iWebContact.